Comparative Pharmacology
Head-to-head clinical analysis: NASALCROM versus OLOPATADINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NASALCROM versus OLOPATADINE HYDROCHLORIDE.
NASALCROM vs OLOPATADINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cromolyn sodium stabilizes mast cells by inhibiting the release of histamine and other mediators of inflammation from sensitized mast cells. The exact molecular mechanism is not fully understood but may involve inhibition of calcium ion influx into mast cells.
Olopatadine hydrochloride is a selective histamine H1 receptor antagonist and mast cell stabilizer. It inhibits histamine release from mast cells and prevents histamine-induced effects such as increased vascular permeability and pruritus.
One spray (5.2 mg) into each nostril 3-4 times daily (maximum 6 times daily).
One drop of 0.1% or 0.2% ophthalmic solution in each affected eye twice daily (every 6-8 hours) for 0.1%; once daily for 0.2%.
None Documented
None Documented
Terminal elimination half-life is 1-2 hours; clinically, due to local mast cell stabilization, systemic levels do not correlate with effect.
Terminal elimination half-life of 8–12 hours in healthy adults; prolonged in hepatic impairment (up to 18 hours)
Primarily unchanged drug; renal excretion accounts for ~90% of elimination, with minor biliary/fecal excretion (<5%).
Primarily renal excretion (60-70% unchanged), with minor biliary/fecal elimination (~30% as metabolites)
Category C
Category A/B
Mast Cell Stabilizer
Antihistamine / Mast Cell Stabilizer